26 results
6-K
EX-99.1
GLPG
Galapagos NV
3 May 24
Galapagos reports first quarter 2024 financial results
9:30am
continuing operations
Assets in disposal group classified as held for sale
Total current assets
Total assets
Equity and liabilities
Share capital … with assets in disposal group classified as held for sale
Total current liabilities
Total liabilities
Total equity and liabilities
Consolidated cash flow
6-K
EX-99.2
GLPG
Galapagos NV
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
from continuing operations 166,803 508,117 Cash and cash equivalents included in assets classified as held for sale 7—Current financial investments … statements, and prior to financial year 2021 also including Fidelta, our fee-for-service business sold to Selvita on 4 January 2021, classified
6-K
EX-99.2
GLPG
Galapagos NV
4 Aug 23
Galapagos announces first half-year 2023 financial results
4:05pm
that are not observable in the market, which are classified as Level 3 inputs. Key assumptions in the valuation at 30 June 2023 include a discount rate of 12.5
6-K
EX-99.1
GLPG
Galapagos NV
5 May 23
Galapagos announces first quarter 2023 financial results
4:05pm
operations
Assets classified as held for sale
Total current assets
Total assets
Equity and liabilities
Share capital
Share premium account
Other … payable
Current deferred income
Current liabilities from continuing operations
Liabilities directly associated with assets classified as held for sale
6-K
EX-99.1
a74u7
24 Feb 22
Galapagos 2021 results set stage for future growth
5:19pm
6-K
EX-99.2
qq4py8lr53 3jzfe3
8 Nov 21
Galapagos reports commercial and operational progress at Q3 financial results
4:03pm
6-K
EX-99.2
lpgfcannch5b906d 78
5 Aug 21
Galapagos reports H1 financial results with refocused pipeline and operational progress
4:02pm
6-K
EX-99.2
zhar xagus73370q5si
11 May 21
Current report (foreign)
2:10pm
6-K
EX-99.2
g9nh32df3fq965jt yan
25 Oct 19
Solid third quarter 2019 performance with strong balance sheet for continued R&D growth
5:00pm
6-K
EX-99
7fg7077fh n6oi9kfk2
25 Jul 19
Strong clinical progress in H1, and transformative collaboration with Gilead announced
4:24pm
6-K
EX-99.2
a2pe5xaolo
26 Apr 19
Galapagos reports on historic first quarter 2019
4:06pm
6-K
EX-99.2
ppa5d9m4wmwq
26 Oct 18
Hallmark third quarter 2018 and Annual R&D Update at Galapagos
4:19pm
424B5
3xiitg9mbwfm40
13 Sep 18
Prospectus supplement for primary offering
12:00am
6-K
EX-99.2
rnzl2thzpc ousma
2 Aug 18
Current report (foreign)
4:03pm
6-K
EX-99.2
v8d730 fykrwjs
27 Apr 18
Galapagos reports first quarter 2018 results
12:00am